H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating and $21 price target on Viking Therapeutics shares after the company announced results from its Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735. The firm says the data provide "a very promising initial look" at VK2735’s potential in obesity and given the recent surge in popularity of prescribing GLP-1/GIP modulators like liraglutide and semaglutide for weight loss its believes VK2735 is "becoming increasingly well-positioned in the space" and emerging as "a heavyweight contender."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VKTX:
- VKTX Soars on Promising VK2735 Data
- Viking Therapeutics initiates Phase 1 study of novel formulation of VK2735
- Viking Therapeutics announces results from Phase 1 trial of VK2735
- Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
- William Blair says Viking bull thesis intact after Altimmune data